Recently, three companies from the fund-of-funds portfolio managed by Yuanhe Chencun successfully passed their review processes.

Among them, two are listed on the STAR Market: Qixinan Group Co., Ltd. (abbreviated as "Qixinan") and Sungene Biotech Co., Ltd. (abbreviated as "Sungene Biotech"); one is listed on the NASDAQ in the U.S.: Beijing Genscript Biotechnology Co., Ltd. (abbreviated as "Genscript," stock code "GTH").

Qianxin is a project jointly invested in 2018 by Yuanhe Chencun and Yuanhe Holdings, along with Yuanhe Capital. The company focuses exclusively on the cybersecurity market, offering next-generation enterprise-level network security products and services tailored for government and corporate clients.

Shengxiang Biotech is a comprehensive in-vitro diagnostics solutions provider that integrates independent innovation in gene technology, focusing on the R&D, manufacturing, and sales of diagnostic reagents and instruments, as well as offering third-party medical testing services.

Genscript is a leading precision cancer healthcare company in China, dedicated to delivering comprehensive, one-stop molecular diagnostic solutions for diverse applications—ranging from cancer diagnosis and monitoring to early screening and drug development services.